NCT06130254View on ClinicalTrials.gov

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

August 25, 2028

Study Completion Date

August 25, 2030

Conditions
Advanced Solid TumorNon-small Cell Lung Cancers
Interventions
DRUG

Adagrasib

Given by PO BID

DRUG

Olaparib

Given by PO BID

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Mirati Therapeutics Inc.
All Listed Sponsors
collaborator

Mirati Therapeutics Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06130254 - Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Biotech Hunter | Biotech Hunter